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Abstract
Background: Dyslipidemia has been associated with hypertension. The present study explored if
polymorphisms in genes encoding proteins in lipid metabolism could be used as predictors for the
individual response to antihypertensive treatment.
Methods: Ten single nucleotide polymorphisms (SNP) in genes related to lipid metabolism were
analysed by a microarray based minisequencing system in DNA samples from ninety-seven
hypertensive subjects randomised to treatment with either 150 mg of the angiotensin II type 1
receptor blocker irbesartan or 50 mg of the β1-adrenergic receptor blocker atenolol for twelve
weeks.
Results: The reduction in blood pressure was similar in both treatment groups. The SNP C711T
in the apolipoprotein B gene was associated with the blood pressure response to irbesartan with
an average reduction of 19 mmHg in the individuals carrying the C-allele, but not to atenolol. The
C16730T polymorphism in the low density lipoprotein receptor gene predicted the change in
systolic blood pressure in the atenolol group with an average reduction of 14 mmHg in the
individuals carrying the C-allele.
Conclusions: Polymorphisms in genes encoding proteins in the lipid metabolism are associated
with the response to antihypertensive treatment in a drug specific pattern. These results highlight
the potential use of pharmacogenetics as a guide for individualised antihypertensive treatment, and
also the role of lipids in blood pressure control.
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Background
Hypertension is a complex trait caused by multiple envi-
ronmental and genetic factors interacting through the car-
diac, vascular and endothelial systems. Several drug
classes with different mechanisms of action, including
inhibitors of the renin-angiotensin-aldosterone system
(RAAS), calcium channel blockers, adrenergic receptor
blockers and diuretics, are available for treatment of
hypertension. However, the response to antihypertensive
treatment is highly variable between individuals, which
makes it difficult to predict the efficacy of a specific drug
in the individual patient [1-3]. Currently, there are no
clinically useful biochemical or metabolic markers for
predicting the individual responses to antihypertensive
treatment [4-6].
Twin studies have estimated that as much as half of the
variability in blood pressure levels between individuals is
due to genetic factors [7,8]. Based on the abundance of
single nucleotide polymorphisms (SNPs) in the human
genome [9], it can be expected that one or more SNPs
occur in each of the genes encoding components of the
blood pressure regulating systems, and that they are the
genetic factors influencing individual blood pressure lev-
els. Coding SNPs affecting the function of enzymes and
receptors in pathways of blood pressure regulation, or reg-
ulatory SNPs, affecting the expression levels of genes, are
likely to explain part of the variability of the response to
antihypertensive treatment. Hence, these functional
SNPs, or other SNPs inherited in linkage disequilibrium
with them, could be potential pharmacogenetic markers
for predicting the response to a certain drug, and thus
guide the selection of the optimal drug for each individual
patient [10-12].
The RAAS and the sympathetic nervous system play key
roles in blood pressure regulation. We have earlier shown
that polymorphisms in the angiotensin converting
enzyme gene [13] and a SNP in the aldosterone synthase
gene [14] are related to changes in blood pressure during
treatment with the angiotensin II receptor blocker irbe-
sartan, whereas two SNPs in the angiotensinogen gene
were associated to the reduction in blood pressure by the
β1-adrenergic receptor blocker atenolol [15]. Dyslipi-
demia with high levels of serum triglycerides and free fatty
acids, and elevated serum cholesterol levels and low levels
of high-density lipoprotein cholesterol are common in
hypertensive patients. Association has been found
between disturbance in lipid metabolism and hyperten-
sion, but so far no attempts have been made to relate var-
iables reflecting lipids, or the genes involved in lipid
metabolism, to the individual response to antihyperten-
sive treatment.
We have recently developed a microarray based minise-
quencing system for parallel genotyping of multiple SNPs
in blood pressure regulating candidate genes [16]. Here
we analysed the relationships between the genotypes of
SNPs in the apolipoprotein A-IV, apolipoprotein A-V,
apolipoprotein B-100, low density lipoprotein receptor,
hepatic lipase and lipoprotein genes and reductions in
blood pressure in hypertensive patients randomised to
monotherapy with either irbesartan or atenolol. We
found that SNP alleles in the apolipoprotein B gene and
the low density lipoprotein receptor gene were associated
to the antihypertensive response after twelve weeks of
treatment.
Methods
Study population
DNA extracted from blood samples from 97 hypertensive
patients from the double blind parallel group "Swedish
Irbesartan Left Ventricular Hypertrophy Investigation ver-
sus Atenolol" (SILVHIA) trial [17] were analysed. Men
and women above the age of 18, having primary mild to
moderate hypertension and left ventricular hypertrophy
were enrolled in the trial and randomised to receive either
150 mg of the angiotensin II type 1 receptor blocker irbe-
sartan or 50 mg of the β1-adrenergic receptor blocker aten-
olol once daily as monotherapy. The dose was doubled
after six weeks if the diastolic blood pressure was ≥ 90
mmHg. Blood pressure was measured by trained nurses
using a mercury sphygmomanometer, after the patients
had rested for at least 10 min in the seated position. Left
ventricular hypertrophy was defined as left ventricular
mass index of > 131 g/m2 for men and > 100 g/m2 for
women, assessed by echocardiography. The data pre-
sented relates to the change in blood pressure after 12
weeks of treatment. For details on the SILVHIA trial, see
Malmqvist  etal  [17]. Baseline characteristics for the
patients are presented in Table 1. The study was approved
by the ethics committees of all participating centres of the
SILVHIA trial and that of the Medical Faculty of Uppsala
University.
SNP markers and genotyping procedure
In our previous study [16], 98 SNPs were selected from the
NCBI (dbSNP, http://www.ncbi.nlm.nih.gov/SNP) and
the SNP Consortium (TSC, http://snp.cshl.org) databases
and validated in a pooled DNA sample representing the
Swedish population. A subset of these SNPs located in
genes involved in lipid metabolism and that were poly-
morphic in the Swedish population were included in the
study presented here, together with one additional SNP in
the apolipoprotein A-V gene. See Table 2 for information
on the SNPs.
Fragments comprising the SNPs were amplified in multi-
plex PCR described previously [16]. A microarray basedBMC Cardiovascular Disorders 2004, 4:16 http://www.biomedcentral.com/1471-2261/4/16
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minisequencing single nucleotide primer extension assay,
in which one or two of four ddNTPs labelled with the
fluorophore Tamra (Perkin Elmer Life Sciences, Boston,
MA, USA) were incorporated by the Thermo Sequenase™
DNA-polymerase at each SNP site. The incorporated
ddNTPs were detected using a fluorescence scanner, and
the fluorescence signals were extracted. A signal intensity
fraction, obtained by dividing the fluorescence signal
intensity for allele 1 with the sum of the fluorescence sig-
nal intensities for allele 1 and allele2, was used to assign
the individual genotypes. The SNP APOA-V C31455T was
genotyped using a microtiter plate minisequencing assay
with tritium detection [18].
Statistical analyses
Analysis of covariance (ANCOVA) with each SNP as fac-
tor, baseline blood pressure as covariate and the change in
blood pressure as response, was performed. The analyses
were performed by treatment group and blood pressure
measurement (systolic and diastolic blood pressures).
Correction for multiple testing was performed by calcula-
tion of critical p-values corresponding to a nominal type I
Table 1: Characteristics of the hypertensive patients in the two treatment groups.
Irbesartan group2 Atenolol group2
Number of patients 48 49
Age (years) 54 ± 8 54 ± 8
Gender (proportion females) 37% 31%
Height (m) 1.74 ± 0.09 1.73 ± 0.09
Weight (kg) 83 ± 15 82 ± 14
Smokers trial start (%) 29 18
Baseline fs-cholesterol (mM) 6.1 ± 1.0 5.8 ± 1.1
Baseline fb-glucose (mM) 5.7 ± 3.1 5.2 ± 2.5
Pre-treatment SBP1 (mmHg) 164 ± 18 160 ± 20
Pre-treatment DBP1 (mmHg) 104 ± 7 103 ± 8
Change in SBP at 12 weeks (mmHg) -16 ± 20 -11 ± 16
Change in DBP at 12 weeks (mmHg) -9.0 ± 11 -12 ± 7.7
1 Systolic blood pressure (SBP) and diastolic blood pressure (DBP)
2 Data are mean ± SD
Table 2: Investigated polymorphisms given as gene names, acronym and GenBank accession number.
Gene name and acronym1 dbSNP ID2 Amino acid alteration SNP name3
Apolipoprotein A-IV rs5092 Thr/Thr A1449G
APOA-IV; J02758
Apolipoprotein A-V rs662799 Promoter C31455T
APOA-V; AC074203
Apolipoprotein B-100 rs1801701 Arg/Gln G10108A†
APOB; M19828†; M19810§ rs1367117 Thr/Ile C711T§
Low density lipoprotein receptor rs688 Asn/Asn C16730T
LDLR; AF217403 rs5925 Val/Val C2000IT
Lipase, hepatic rs6083 Asn/Ser A110G
LIPC; M35429
Lipoprotein rs328 Ser/Term C9040G
LPL; AF050163 rs312 Intron G7315C
rs314 Intron A7360G
1 Gene name and acronym, GenBank accession number http://www.ncbi.nlm.nih.gov/ for the sequence used in the design of primers for the PCR 
and minisequencing reactions.
2 SNP identification number in the NCBI SNP database dbSNP, http://www.ncbi.nlm.nih.gov/SNP.
3 Corresponding to the nucleotide position in the gene sequence referenced in the first column and the nucleotide variation in the coding strand.BMC Cardiovascular Disorders 2004, 4:16 http://www.biomedcentral.com/1471-2261/4/16
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error of 5% using a permutation test [19]. Two tailed sig-
nificance levels were used.
Results and discussion
We explored possible associations between individual
genotypes of ten SNPs and reduction in systolic and
diastolic blood pressure as response to treatment with
atenolol or irbesartan (Figure 1) in samples from the SIL-
VHIA trial [17]. In the irbesartan group, a change in systo-
lic blood pressure appeared to be related to genotype for
the SNPs ApoA-IV A1449G, ApoA-V C31455T and ApoB
C711T. In the atenolol treatment group, presence of the
C-allele of the SNP LDLR C16730T was associated to the
reduction in systolic blood pressure.
Correction for multiple testing using a permutation test
[19] yielded critical p-values of 0.004 and 0.007 for systo-
lic blood pressure after atenolol and irbesartan treatment,
respectively, and 0.006 and 0.007 for the diastolic blood
pressure, corresponding to the significance level of p =
0.05. After the permutation test, carriership of the C-allele
of the C711T SNP in the apolipoprotein B gene remained
significantly associated to the reduction in systolic blood
pressure (p = 0.004) in the irbesartan treatment group
(Figure 1) while the individuals homozygous for the T-
allele showed no reduction in systolic blood pressure. The
same pattern of response related to genotype was seen for
diastolic blood pressure, although it did not reach statisti-
cal significance. In the atenolol treatment group, the SNP
C16730T in the low density lipoprotein receptor gene
showed a trend of association to the reduction in systolic
blood pressure. Presence of the C-allele was related to
blood pressure reduction (p = 0.006), while the individu-
als homozygous for the T-allele (n = 9) actually showed an
increase in systolic blood pressure (Figure 1). A similar
response pattern was not seen for the diastolic blood pres-
sure during atenolol treatment (p = 0.44) (Figure 1). There
were 39 carriers of the favourable C-allele of the APOB
C711T SNP in the irbesartan treatment group. The average
reduction in systolic blood pressure for these individuals
was 19 mmHg, compared to 0 mmHg for the individuals
lacking this allele. In the atenolol treatment group, the
individuals carrying the favourable C-allele of the SNP
LDLR C16730T showed an average reduction of 14
mmHg in systolic blood pressure compared to an increase
of 7.5 mmHg for the individuals homozygous for the T-
allele.
The SNP C711T in the apolipoprotein B gene is located in
the coding region of the gene, and alters a threonine resi-
due to an isoleucine residue in the protein. This SNP is
located in the amino-terminal part of the enzyme and has
been suggested to affect the dimerisation of apolipopro-
tein B and low density lipoprotein during cholesterol
transport [20]. The C16730T SNP in the LDLR gene results
in a synonymous amino acid change, however this SNP
could be in linkage disequilibrium with another func-
tional SNP potentially influencing the response to drug
treatment. Irrespectively if the tested SNPs are actually
functional, our findings imply a potential connection
between lipid metabolism and response to antihyperten-
sive treatment.
We have recently found circulating apolipoprotein B to be
the most powerful predictor of endothelium-dependent
vasodilation of the commonly used markers of choles-
terol metabolism [21]. It is not evident, however, why
apolipoproteins predict the response to irbesartan, and
not to atenolol treatment, as these drugs appear to
improve endothelium-dependent vasodilation to a simi-
lar extent [22]. Lipid abnormalities, commonly seen in
hypertension, have been considered to be connected to
the blood pressure level by the common denominators
obesity and insulin resistance. Other studies have sug-
gested a more direct effect of lipids in blood pressure con-
trol, as infusion of the fat emulsion Intralipid together
with heparin increases blood pressure in healthy subjects
[23-25]. This effect is more pronounced in the normoten-
sive subjects with a family history of hypertension [26]. It
has also been shown that an acute elevation of free fatty
acids alters heart rate variability, an index of cardiac auto-
nomic nervous system balance [27], suggesting that lipid
metabolism may be involved in the regulation of cardio-
vascular autonomic tone. Thus our results that indicate
involvement of components of lipid metabolism in the
response to antihypertensive treatment are supported by
cross-sectional epidemiological studies.
In our earlier exploratory study, 74 SNPs with a minor
allele frequency over 5%, including nine of the SNPs ana-
lysed here were tested as predictors of blood pressure reg-
ulation in the SILVHIA study samples using a multiple
regression model [16]. The main aim of this study was to
establish the microarray-based genotyping system. Analy-
sis of twenty-eight SNPs from this panel that are located in
genes from the renin-angiotensin aldosterone system
identified a SNP in the aldosterone synthase gene
(CYP11B2 T267C) and two SNPs in the angiotensinogen
gene (AGT G1218A and T1198C) that appeared to be
associated to blood pressure reduction [14,15]. A limita-
tion in these previous studies was that correction for mul-
tiple testing was not applied, whereas in the current study
we used a permutation test.
A remaining weakness in our study is the small number of
samples available for analysis, which does not allow
detection of small to medium size gene effects, and results
in uncertain estimation of the the magnitude of the effects
detected. Moreover, in a small study there is the risk of a
non-representative group of patients with respect toBMC Cardiovascular Disorders 2004, 4:16 http://www.biomedcentral.com/1471-2261/4/16
Page 5 of 7
(page number not for citation purposes)
Effect of SNP genotype on the change in blood pressure after 12 weeks of treatment for the ten SNPs Figure 1
Effect of SNP genotype on the change in blood pressure after 12 weeks of treatment for the ten SNPs. For each of the SNPs, 
the pattern of change in blood pressure related to genotype is illustrated for the systolic blood pressure (SBP) and diastolic 
blood pressure (DBP) in separate panels. In each panel, the mean change in blood pressure is shown for the SNP genotypes in 
the atenolol treatment group on the left, and the corresponding results in the irbesartan treatment group are given on the 
right. The error bars corresponds to the standard error of the mean. The p-values indicating significance for the APOA-IV 
A1449G, APOA-V C31455T, APOB C711T and LDLR C16730T SNPs are given in the corresponding panels. The number of 
individuals of each genotype is shown above the bars in each panel.BMC Cardiovascular Disorders 2004, 4:16 http://www.biomedcentral.com/1471-2261/4/16
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gender, age, and genotype distribution. Despite these lim-
itations, we detected a significant effect of the SNP C711T
in the apolipoprotein B gene and the SNP C16730T in the
low density lipoprotein receptor after correction for
multiple testing. The pharmacogenetically interesting
results from our study need to be replicated in other
studies.
As the C711T SNP in the apolipoprotein B gene predicted
response to treatment with irbesartan, and the C16730T
SNP in the low density lipoprotein receptor gene
appeared to predict response to atenolol treatment, our
results point at possible use of SNPs in genes encoding
components of lipid metabolism in pharmacogenetic
panels for selecting the optimal drug for each patient. To
our knowledge our study is the first one to investigate the
relationship between polymorphisms in genes involved
in lipid metabolism and the response to antihypertensive
treatment.
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